{"disease":{"id":"erythroleukoplakia","name":"erythroleukoplakia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07318922","title":"Evaluation of Artificial Intelligence in Diagnosis and Risk Assessment of Oral Potentially Malignant Disorders","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT03603223","title":"Pembrolizumab in Treating Participants With Leukoplakia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03279744","title":"A Study to Evaluate the Efficacy and Safety of Radion™-Pdt in Patients With Oral Precancerous Lesion","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Pharma Power Biotec Co., Ltd.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}